drugset / Trial / NCT01363076

The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years

NCT01363076

Phase 1 Completed 20 enrolled Egalet Ltd
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This was an open-label PK study in pediatric subjects who had undergone general surgery. Each subject's study participation consisted of a screening visit, a single-dose treatment with intranasal ketorolac (IN) tromethamine, and a follow-up visit. Following surgery, subjects received IN ketorolac 15 mg (weight \< 50 kg) or 30 mg (weight \> or = 50 kg) when pain relief was indicated. For pain not relieved by the study drug, the subjects had access to an opioid analgesic administered by patient-controlled analgesia (PCA). Blood samples for pharmacokinetic analysis were obtained at specified time points following the dose of ketorolac.

Timeline

Start
2007-06
Primary completion
2008-01
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 15 mg Intranasal
Subject Ketorolac Other / unclassified 30 mg Intranasal

Indications

No indication recorded.